And one of them is pharmaceutical giant Pfizer ( PFE +1.98%). Now, with a major step along the path to entering this ...
On November 18, JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) to $1,150 from $1,050 while maintaining an Overweight ...
Novo Nordisk faces setbacks with semaglutide in Alzheimer's trials and declining growth. Read here for analyst outlook and ...
Inflammatory bowel disease (IBD) has expanded beyond its initial confines of early industrialised countries in North America, Europe, and Oceania and now constitutes a global illness. Once rare in the ...
Medicare will save approximately $12 billion, or 44%, on 15 high-cost medications as a result of the second round of the ...
As pharmaceutical companies rapidly expand direct-to-consumer (DTC) models amid shifting US drug pricing reforms and the upcoming launch of TrumpRx, experts warn that these approaches introduce as ...
Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.
Power Women Summit, presented by STARZ #TakeTheLead is expanding the dynamic lineup of trailblazers redefining culture, ...
13h
Analysis-Undeterred by Novo Nordisk failure, scientists consider GLP-1s as Alzheimer's prevention
Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...
Background: In January, Greystar was named as a defendant in an antitrust lawsuit filed by California Attorney General Rob ...
Some studies have found that about half of people who start taking a GLP-1 drug for weight loss stop taking it within a ...
Novo Nordisk A/S is rated a Strong Buy with a huge unmet demand in obesity treatment and a low 13x P/E ratio. Learn more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback